The clinical features, outcomes, differential diagnoses, epidemiology, risk factors, and treatment approaches to tardive drug-induced extrapyramidal syndromes (EPS) are reviewed. Tardive forms of dyskinesia (TD), dystonia (TDt), akathisia (TA), Gilles de la Tourette syndrome (TGTS), myoclonus (TM), and parkinsonism (TP) are described. Moreover, pharmacological and topographical subtypes of TD are discussed. While TD, TDt, and TA are clearly delineated syndromes, there are limited data on TGTS, TM, and the questionable TP. TDt is distinguished from TD by clinical and treatment-related variables. Epidemiological studies provide evidence of better prognosis for TD compared with both TDt and TA. Two distinct groups of variables were found to be associated with a higher risk for TD: an exogenous factor (neuroleptic treatment variables and alcohol or drug abuse) and a factor of predisposition (elderly, female, affective disorder diagnosis, presence of EPS, diabetes mellitus type II, and signs of central vulnerability). In contrast, being younger and male was associated with TDt. A significant relationship between the hyperkinetic forms of tardive EPS was confirmed. Therapeutic strategy differs for the mild, moderate, and severe forms of tardive EPS. Using low doses of antipsychotics is a good preventive approach. Reducing the dose or switching to an atypical antipsychotic is the usual, but not yet fully explored, first therapeutic step. Clozapine, an antipsychotic with antidyskinetic and antidystonic effectiveness, is the second treatment step. Various suppressors of tardive movements were tested in controlled trials, mainly in TD. GABAergic benzodiazepines (clonazepam), adrenergic antagonists (propranolol, clonidine), antioxidants (α-tocopherol), and calcium channel blockers (nifedipine) are useful in the third step of treatment of more severe tardive EPS. Unlike TD, TDt and (partially) TA improve on higher doses of anticholinergic medication. Local injection of botulinum A toxin markedly ameliorates focal tardive dystonia over several months. Less verified therapeutic interventions are discussed.
References
-
1
Adityanjee, Chan T M, Subramaniam M.
Temporary remission of tardive dystonia following electroconvulsive therapy.
Br J Psychiatry.
1990;
156
433-435
-
2
Andreassen O A, MacEwan T, Gulbrandsen A K, McCreadie R G, Steen V M.
Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
Psychopharmacology (Berlin).
1997;
131
174-179
-
3
American College of Neuropharmacology - Food and Drug Administration Task Force .
Neurological syndromes associated with antipsychotic drug use.
Arch Gen Psychiatry.
1973;
28
463-467
-
4
Armstrong M, Daly A K, Blennerhassett R, Ferrier N, Idle J R.
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.
Br J Psychiatry.
1997;
170
23-26
-
5
Aronson T A.
Persistent drug-induced parkinsonism.
Biol Psychiatry.
1985;
20
795-798
-
6
Arthur H, Dahl M L, Siwers B, Sjöqvist F.
Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.
J Clin Psychopharmacol.
1995;
15
211-216
-
7
Asnis G M, Leopold M A, Duvoisin R C, Schwartz A H.
A survey of tardive dyskinesia in psychiatric outpatients.
Am J Psychiatry.
1977;
134
1367-1370
-
8
Bailey L G, Maxwell S, Brandabur M M.
Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
Psychopharmacol Bull.
1997;
33
177-181
-
9 Baldessarini R J, Tarsy D. Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF, editors Psychopharmacology: A generation in progress. New York; 1st ed. Raven Press 1978: 993-1004
-
10
Barnes T RE, Braude W M.
Akathisia variants and tardive dyskinesia.
Arch Gen Psychiatry.
1985;
42
874-878
-
11
Barnes T RE, Kidger T, Gore S M.
Tardive dyskinesia: a 3-year follow-up study.
Psychol Med.
1983;
13
71-81
-
12
Bergen J, Kitchin R, Berry G.
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
Biol Psychiatry.
1992;
32
580-594
-
13
Bharucha K J, Sethi K D.
Tardive tourettism after exposure to neuroleptic therapy.
Mov Disord.
1995;
10
791-793
-
14
Bobruff A, Gardos G, Tarsy D, Rapkin R M, Cole J O, Moore P.
Clonazepam and phenobarbital in tardive dyskinesia.
Am J Psychiatry.
1981;
138
189-193
-
15
Braun V, Richter H P.
Selective peripheral denervation for the treatment of spasmodic torticollis.
Neurosurgery.
1994;
35
58-62
-
16
Braude W M, Barnes T RE, Gore S M.
Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admission.
Br J Psychiatry.
1983;
143
139-150
-
17
Brown K W, White T.
Pseudoakathisia and schizophrenic negative symptoms.
Acta Psychiatr Scand.
1991;
84
107-109
-
18
Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan E O.
Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.
Acta Psychiatr Scand.
1996;
94
118-124
-
19 Burke R E. Tardive akathisia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 409-424
-
20
Burke R E, Fahn S, Jankovic J, Marsden C D, Lang A E, Gollomp S, Illson J.
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.
Neurology.
1982;
32
1335-1346
-
21
Burke R E, Kang U J, Jankovic J, Miller L G, Fahn S.
Tardive akathisia: an analysis of clinical features and response to open therapeutic trial.
Mov Disord.
1989;
4
157-175
-
22
Cadet J L, Lohr J B, Jeste D V.
Free radicals and tardive dyskinesia (letter).
Trends Neurosci.
1986;
9
107-108
-
23
Caine E D, Polin R J, Kartzinel R, Ebert M H.
The trial use of clozapine for abnormal involuntary movement disorders.
Am J Psychiatry.
1979;
136
317-320
-
24
Caracci G, Mukherjee S, Roth S D, Decina P.
Subjective awareness of abnormal involuntary movements in chronic schizophrenic patients.
Am J Psychiatry.
1990;
147
295-298
-
25
Carroll B J, Curtis J, Komken E.
Paradoxical response to dopamine agonists in tardive dyskinesia.
Am J Psychiatry.
1977;
137
785-789
-
26
Casey D E.
Spontaneous and tardive dyskinesias: clinical and laboratory studies.
J Clin Psychiatry.
1985;
46
42-47
-
27
Casey D E.
Affective disorder and tardive dyskinesia.
Encephale.
1988;
14
221-226
-
28
Casey D E.
Clozapine: neuroleptic-induced EPS and tardive dyskinesia.
Psychopharmacol Bull.
1989;
99
S47-S53
-
29
Casey D E, Denney D.
Pharmacological characterization of tardive dyskinesia.
Psychopharmacology.
1977;
54
1-8
-
30
Casey D E, Gardos G.
Tardive dyskinesia: outcome at 10 years.
Schizophr Res.
1990;
3
11
-
31 Casey D E, Hansen T E. Spontaneous dyskinesia. In: Jeste DV, Wyatt RJ, editors Neuropsychiatric movement disorders. Washington (DC); 1st ed. American Psychiatric Press 1984: 68-95
-
32
Casey D E, Rabins P.
Tardive dyskinesia as a life-threatening illness.
Am J Psychiatry.
1978;
135
486
-
33
Chakos M H, Alvir J M, Woerner M G, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane J M, Borenstein M, Lieberman J A.
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
Arch Gen Psychiatry.
1996;
53
313-319
-
34
Chiu H F, Leung J, Li K W.
Tardive dystonia and diffuse idiopathic skeletal hyperostosis.
Singapore Med J.
1991;
32
94-95
-
35
Chouinard G.
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicentre Risperidone Study.
J Clin Psychopharmacol.
1995;
15 (suppl 1)
36-44
-
36
Chouinard G, Annable L, Ross-Chouinard A, Nestoros J N.
Factors related to tardive dyskinesia.
Am J Psychiatry.
1979;
136
79-83
-
37
Chouinard G, Boisvert D, Bradwejn J.
Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug.
Can Med Assoc J.
1982;
126
821-827
-
38
Chouinard G, Annable L, Mercier P, Ross-Chouinard A.
A five year follow-up study of tardive dyskinesia.
Psychopharmacol Bull.
1986;
22
259-263
-
39
Chouinard G, Annable L, Ross-Chouinard A, Mercier P.
A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.
J Clin Psychopharmacol.
1988;
8 (suppl 4)
21S-26S
-
40
Cohen B M, Keck P E, Satlin A, Cole J O.
Prevalence and severity of akathisia in patients on clozapine.
Biol Psychiatry.
1991;
29
1215-1219
-
41
Cole J O, Gardos G, Boling L A, Marby D, Haskell D, Moore P.
Early dyskinesia - vulnerability.
Psychopharmacology.
1992;
107
503-510
-
42
Crane G E.
Persistence of neurological symptoms due to neuroleptic.
Am J Psychiatry.
1971;
127
1407-1410
-
43
Crane G E.
Persistent dyskinesia.
Br J Psychiatry.
1973;
122
395-405
-
44
Crane G E, Naranjo E R.
Motor disorders induced by neuroleptics. (A proposal new classification).
Arch Gen Psychiatry.
1971;
24
179-184
-
45
Dave M.
Clozapine-related tardive dyskinesia.
Biol Psychiatry.
1994;
35
886-887
-
46
DeKeyser J, D'Haenen H.
Disappearance of akathisia following electroconvulsive treatment.
Clin Neuropharmacol.
1986;
9
563-565
-
47
Dixon L, Weiden P, Haag G, Sweeney J, Frances A J.
Increased tardive dyskinesia in alcohol-abusing schizophrenic patients.
Compr Psychiatry.
1992;
33
121-122
-
48
Egan M F, Apud J, Wyatt R J.
Treatment of tardive dyskinesia.
Schizophr Bull.
1997;
23
583-609
-
49
Engelhardt D M, Polizos P, Waizer J.
CNS consequences of psychotropic drug withdrawal in autistic children: a follow-up report.
Psychopharmacol Bull.
1975;
11
6-7
-
50
Factor S A, Friedman J H.
The emerging role of clozapine in the treatment of movement disorders.
Mov Disord.
1997;
12
483-496
-
51
Fahn S.
High-dose anticholinergic therapy in dystonia.
Neurology.
1983;
33
1255-1261
-
52
Fahn S.
A therapeutic approach to tardive dyskinesia.
J Clin Psychiatry.
1985;
46
19-24
-
53
Fahn S, Marsden D, van Woert M H.
Definition and classification of myoclonus.
Adv Neurol..
1986;
43
1-5
-
54
Fann W E, Stafford J E, Malone R L, Frost J D, Richman B W.
Clinical research techniques in tardive dyskinesia.
Am J Psychiatry.
1977;
134
759-762
-
55
Faurbye A, Rasch P J, Peterson P B, Brandborg G, Pakkenberg G.
Neurological symptoms in pharmacotherapy of psychoses.
Acta Psychiatr Scand.
1964;
40
10-27
-
56
Feltner D E, Hertzman M.
Progress in the treatment of tardive dyskinesia: theory and practice.
Hospital and Community Psychiatry.
1993;
44
25-34
-
57
Fibiger H C, Lloyd K G.
Neurobiological substances of tardive dyskinesia: the GABA hypothesis.
Trends Neurosci.
1984;
7
462-464
-
58
Fitzgerald P M, Jankovic J.
Tardive oculogyric crises.
Neurology.
1989;
39
1434-1437
-
59
Fleischhacker W W, Miller C H, Barnas C, Bergmann K, Perovich R, Alvir J M, Lieberman J A, Kane J M.
The effect of activation procedures on neuroleptic-induced akathisia.
Br J Psychiatry.
1993;
163
781-784
-
60
Friedman J H, Kucharski L T, Wagner R L.
Tardive dystonia in a psychiatric hospital.
J Neurol Neurosurg Psychiatry.
1987;
50
801-803
-
61
Friis T, Christensen T R, Gerlach J.
Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism, and hyperkinesia.
Acta Psychiatr Scand.
1983;
67
178-187
-
62
Fukuzako H, Tominaga H, Izumi K, Koja T, Nomoto M, Hokazono Y, Kamei K, Fujii H, Fukuda T, Matsumoto K.
Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients.
Biol Psychiatry.
1990;
27
1116-1126
-
63
Ganzini L, Casey D E, Hoffman W F, Heintz R T.
Tardive dyskinesia and diabetes mellitus.
Psychopharmacol Bull.
1992;
28
281-286
-
64
Gardos G.
A case of withdrawal dyskinesia.
Am J Psychiatry.
1979;
136
1099
-
65
Gardos G, Cole J O.
Tardive dyskinesia and anticholinergics drugs.
Am J Psychiatry.
1983;
140
200-202
-
66
Gardos G, Cole J O.
The evaluation and treatment of neuroleptic-induced movement disorders.
Harvard Rev Psychiatry.
1995;
3
130-139
-
67 Gardos G, Cole J O. Tardive dyskinesia and affective disorder. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 69-81
-
68
Gardos G, Cole J O, LaBrie R A.
Drug variables in the etiology of tardive dyskinesia: application of discriminant function analysis.
Prog Neuropsychopharmacol.
1977;
1
147-154
-
69
Gardos G, Cole J O, Schniebolk S, Salomon M.
Comparison of severe and mild tardive dyskinesia: implication for etiology.
J Clin Psychiatry.
1987a;
48
359-362
-
70
Gardos G, Cole J O, Salomon M, Schniebolk S.
Clinical forms of severe tardive dyskinesias.
Am J Psychiatry.
1987b;
144
895-902
-
71
Gardos G, Cole J O, Haskell D, Marby D, Paine S S, Moore P.
The natural history of tardive dyskinesia.
J Clin Psychopharmacol.
1988;
8 (suppl 4)
31S-37S
-
72
Gardos G, Casey D E, Cole J O, Perényi A, Kocsis E, Arato M, Samson J A, Conley C.
Ten-year outcome of tardive dyskinesia.
Am J Psychiatry.
1994;
151
836-841
-
73
Gerlach J.
Relationship between tardive dyskinesia, L-dopa-induced hyperkinesia and parkinsonism.
Psychopharmacology.
1977;
51
259-263
-
74
Gerlach J, Casey D E.
Tardive dyskinesia.
Acta Psychiatr Scand.
1988;
77
369-378
-
75
Gerlach J, Peacock L.
Intolerance to neuroleptic drugs: the art of avoiding extrapyramidal syndromes.
Eur Psychiatry.
1995;
10 (suppl 1)
27-31
-
76
Gerlach J, Koppelhus E, Helweg E, Monrad A.
Clozapine and haloperidol in a single-blind crossover trial: therapeutic and biochemical aspects in the treatment of schizophrenia.
Acta Psychiatr Scand.
1974;
50
410-424
-
77
Gibb W R, Lees A J.
The clinical phenomenon of akathisia.
J Neurol Neurosurg Psychiatry.
1986;
49
861-866
-
78
Gimenez-Roldan S, Mateo D, Bartolome P.
Tardive dystonia and severe dyskinesia.
Acta Psychiatr Scand.
1985;
71
488-494
-
79
Glazer W M, Morgenstern H, Niedzwiecki D, Hughes J.
Heterogeneity of tardive dyskinesia: a multivariate analysis.
Br J Psychiatry.
1988;
152
253-259
-
80
Glazer W M, Morgenstern H, Doucette J T.
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
J Clin Psychiatry.
1993;
54
133-139
-
81
Godwin-Austen R B, Clark T.
Persistent phenothiazine dyskinesia treated with tetrabenazine.
BMJ.
1971;
4
25-26
-
82
Granacher R P Jr.
Differential diagnosis of tardive dyskinesia: an owerview.
Am J Psychiatry.
1981;
130
1288-1297
-
83 Greene P. Tardive dystonia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 395-408
-
84
Greil W, Haag H, Rossangl G.
Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study.
Br J Psychiatry.
1984;
145
304-310
-
85
Gureje O.
Topographic subtypes of tardive dyskinesia in schizophrenic patients less than 60 years of age.
J Neurol Neurosurg Psychiatry.
1988;
51
1225-1230
-
86
Gureje O.
The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors.
Psychol Med (London).
1989;
19
121-128
-
87
Hallet M, Chadwick D, Marsden C D.
Cortical reflex myoclonus.
Neurology.
1979;
29
1107-1125
-
88
Halstead S M, Barnes T RE, Speller J C.
Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.
Br J Psychiatry.
1994;
164
177-183
-
89
Hamer R M.
Tongue, arms, face movement enough to assess dyskinesia.
Clin Psychiatr News.
1982;
10
22
-
90
Hanin B, Lerner Y, Srour N.
An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia.
Convuls Ther.
1995;
11
271-274
-
91 Hansen T E, Hoffman W F. Drug-induced parkinsonism. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1995: 341-380
-
92
Hay D P, Hay L, Blackwell B, Spiro H R.
ECT and tardive dyskinesia.
J Geriatr Psychiatry Neurol.
1990;
3
106-109
-
93
Huang C C, Wang R IH, Hasegawa A, Alverno L.
Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.
Psychopharmacology.
1981;
73
359-362
-
94
Inada T, Ichikawa T, Kato Y. et al .
A case of tardive akathisia.
Japan J Psychiatric Treat.
1988;
3
772-774
-
95
Inada T, Yagi G, Kamijima K, Ohnishi K, Kamisada M, Takamiya M, Nakajima S, Rockhold R W.
A statistical trial of subclassification for tardive dyskinesia.
Acta Psychiatr Scand.
1990;
82
404-407
-
96
Jaffe E, Trémeau F, Sharif Z, Reider R.
Clozapine in tardive Tourette syndrome.
Biol Psychiatry.
1995;
38
196-197
-
97
Jeste D V, Wyatt R D.
In search of treatment for tardive dyskinesia: review of the literature.
Schizophr Bull.
1979;
5
251-293
-
98
Jeste D V, Wyatt R D.
Changing epidemiology of tardive dyskinesia: an overview.
Am J Psychiatry.
1981;
138
297-309
-
99 Jeste D V, Wyatt R D. Understanding and treating tardive dyskinesia. New York; 1st ed. Guilford Press 1982
-
100
Jeste D V, Potkin S G, Sinha S, Feder S, Wyatt R J.
Tardive dyskinesia - reversible and persistent.
Arch Gen Psychiatry.
1979;
36
585-590
-
101
Jeste D V, Lohr J B, Clark K, Wyatt R J.
Pharmacological treatments of tardive dyskinesia in the 1980s.
J Clin Psychopharmacol.
1988;
8(suppl 4)
38S-48S
-
102
Jeste D V, Caligiuri M P, Paulsen J S, Heaton R K, Lacro J P, Harris M J, Bailey A, Fell R L, McAdams L A.
Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
Arch Gen Psychiatry.
1995;
52
756-765
-
103
Kabeš J, Sikora J, Pišvejc J, Star¿ O.
Subchronic administration of piracetam in tardive dyskinesia - placebo controlled cross-over comparison.
Activ Nerv Super (Prague).
1985;
27
63-64
-
104
Kalian M, Lerner V, Goldman M.
Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine.
J Nerv Ment Dis.
1993;
181
649-651
-
105
Kane J M, Smith J M.
Tardive dyskinesia. Prevalence and risk factors, 1959 - 1979.
Arch Gen Psychiatry.
1982;
39
473-481
-
106
Kane J M, Wegner J, Stenzler S, Pamsey P.
The prevalence of presumed tardive dyskinesia in psychiatric in-patients and out-patients.
Psychopharmacology.
1980;
69
247-251
-
107
Kane J M, Woerner M, Borenstein M, Wegner J, Lieberman J.
Integrating incidence and prevalence of tardive dyskinesia.
Psychopharmacol Bull.
1986;
22
254-258
-
108
Kane J M, Woerner M, Lieberman J.
Tardive dyskinesia: prevalence, incidence, and risk factors.
J Clin Psychopharmacol.
1988;
8(Aug suppl)
52S-56S
-
109
Kang U J, Burke R E, Fahn S.
Natural history and treatment of tardive dystonia.
Mov Disord.
1986;
1
193-208
-
110
Karagianis J L, Nagpurkar R.
A case of Tourette syndrome developing during haloperidol treatment.
Can J Psychiatry.
1990;
35
228-232
-
111
Karson K N, Jeste D V, LeWitt P A, Wyatt R J.
A comparison of two iatrogenic dyskinesias.
Am J Psychiatry.
1984;
140
1504-1506
-
112
Kaufmann C A, Jeste D V, Shelton R C, Linnoila M, Kafka M S, Wyatt R J.
Noradrenergic and neuroradiological abnormalities in tardive dyskinesia.
Biol Psychiatry.
1986;
21
799-812
-
113
Kazamatzuri H, Chien C-P, Cole J O.
Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
Arch Gen Psychiatry.
1972;
27
95-99
-
114
Kazamatzuri H, Chien C-P, Cole J O.
Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
Am J Psychiatry.
1973;
130
479-483
-
115
Keegan D I, Rajput A H.
Drug-induced dystonia tarda - treatment with L-dopa.
Dis Nerv Syst.
1973;
38
167-169
-
116
Keepers G A, Casey D E.
Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.
Am J Psychiatry.
1991;
148
85-89
-
117
Kidger T, Barnes T R E, Trauer T, Taylor P J.
Sub-syndromes of tardive dyskinesia.
Psychol Med (London).
1980;
10
19-20
-
118
Klawans H L.
The pharmacology of tardive dyskinesia.
Am J Psychiatry.
1973;
130
82-86
-
119
Klawans H L Jr, Bergen D, Bruyn G W.
Prolonged drug-induced parkinsonism.
Confinia Neurologica.
1973;
35
368-377
-
120
Klawans H L, Falk D K, Nausieda P A, Weiner W J.
Gilles de la Tourette syndrome after long term chlorpromazine therapy.
Neurology.
1978;
28
1064-1068
-
121
Klawans H L, Tanner C M, Barr A.
The reversibility of “permanent” tardive dyskinesia.
Clin Neuropharmacol.
1984;
7
153-159
-
122 Klawans H L, Curvey P M, Tanner C M, Goetz C G. Drug-induced myoclonus. In: Fahn S, Marsden CD, van Woert MH, editors Advances in neurology. Vol 43. 1st ed. New York: Raven Press 1986: 251-264
-
123
Ko G N, Zhang L D, Yan W W, Zhang M D, Buchner D, Xia Z Y, Wyatt R J, Jeste D V.
The Shanghai 800: prevalence of tardive dyskinesia in a chinese psychiatric hospital.
Am J Psychiatry.
1989;
146
387-389
-
124
Kobayashi R M.
Drug therapy of tardive dyskinesia.
N Engl J Med.
1977;
296
257-260
-
125
Kruse W.
Persistent muscular restlessness after phenothiazine treatment: report of three cases.
Am J Psychiatry.
1960;
117
152-153
-
126
Kucharski L T, Smith J W, Dunn D D.
Mortality and tardive dyskinesia.
Am J Psychiatry.
1978;
135
1228
-
127
Kuniyoshi M, Inanaga K, Arikawa K, Maeda Y, Nakamura J, Uchimura N.
A case of tardive Tourette-like syndrome.
Jpn J Psychiatry Neurol.
1992;
46
67-70
-
128
Kurz M, Hummer M, Oberbauer H, Fleischhacker W W.
Extrapyramidal side-effects of clozapine and haloperidol.
Psychopharmacology.
1995;
118
52-56
-
129
Lauciello F, Appelbaum M.
Prosthodontic implications of tardive dyskinesia.
NY State Dent J.
1977;
43
214-217
-
130
Lazarus A L, Toglia J U.
Fatal myoglobinuric renal failure in a patient with tardive dyskinesia.
Neurology.
1985;
35
1055-1057
-
131
Lieberman J A, Lesser M, Johns C, Pollack S, Saltz B, Kane J M.
Pharmacological studies of tardive dyskinesia.
J Clin Psychopharmacol.
1988a;
8 (suppl)
57-63
-
132
Lieberman J A, Pollack S, Lesser M, Kame J M.
Pharmacological characterization of tardive dyskinesia.
J Clin Psychopharmacol.
1988b;
8
254-260
-
133
Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J M.
The effect of clozapine on tardive dyskinesia.
Br J Psychiatry.
1991;
158
503-510
-
134
Little J T, Jankovic J.
Tardive myoclonus.
Mov Disord.
1987;
2
307-312
-
135
Mackay A V P, Sheppard G G.
Pharmacotherapeutic trials in tardive dyskinesia.
Br J Psychiatry.
1979;
135
489-499
-
136
Manos N, Gkiouzepas J, Logothetis J.
The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
Am J Psychiatry.
1981;
138
184-188
-
137
Maršálek M.
Do antidepressants increase risk of suicide?.
CS Psychiat.
1998;
94
272-281
-
138
Maršálek M, Roth Z.
Subtypes of tardive dyskinesia.
Clin Neuropsychopharmacol.
1992;
15 (suppl 1)
268 B
-
139
McClelland H A, Dutta D, Metcalf A, Kerr T A.
Mortality and facial dyskinesia.
Br J Psychiatry.
1986;
148
310-316
-
140
McCreadie R G, Robertson L J, Wiles D H.
The Nisthsdale Schizophrenia Surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
Br J Psychiatry.
1992;
161
793-799
-
141
Meltzer H Y.
Treatment of the neuroleptic-nonresponsive schizophrenic patient.
Schizophr Bull.
1992;
18
515-542
-
142
Miller L G, Jankovic J.
Neurologic approach to drug-induced movement disorders: a study of 125 patients.
South Med J.
1990;
83
525-532
-
143
Moore D C, Bowers M B Jr.
Identification of a tardive dyskinesia patients by pharmacologic probes.
Am J Psychiatry.
1980;
137
1202-1205
-
144
Morgenstern H, Glazer W M.
Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications.
Arch Gen Psychiatry.
1993;
50
723-733
-
145
Morgenstern H, Glazer W M, Gibowski L D, Holmbey S.
Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatients population.
J Chronic Dis.
1987;
40
319-327
-
146
Mueller J, Aminoff M J.
Tourette-like syndrome after long-term neuroleptic treatment.
Br J Psychiatry.
1982;
141
191-193
-
147 Mukherjee S, Mahadik S P. Diabetes mellitus and tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 82-98
-
148
Mukherjee S, Bilder R M, Sakeim H A.
Tardive dyskinesia and glucose metabolism (letter).
Arch Gen Psychiatry.
1986a;
43
192-193
-
149
Mukherjee S, Rosen A M, Caracci G, Shukla S.
Persistent tardive dyskinesia in bipolar patients.
Arch Gen Psychiatry.
1986b;
43
342-346
-
150
Myslobodsky M S, Holden T, Sandler R.
Asymmetry of abnormal involuntary movements: a prevalence study.
Biol Psychiatry.
1984;
19
623-628
-
151
Naber D, Leppig M, Grohmann R, Hippius H.
Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients.
Psychopharmacology.
1989;
99
S73-S76
-
152
Nelli A C, Yarden P E, Guazelli M, Feinberg I.
Parkinsonism following neuroleptic withdrawal (letter).
Arch Gen Psychiatry.
1989;
46
383-384
-
153
Olivera A A, Kiefer M W, Manley N K.
Tardive dyskinesia in psychiatric patients with substance use disorders.
Am J Drug Alcohol Abuse.
1990;
16
57-66
-
154
Osborne T E, Grace E G, Schwartz M K.
Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: a literature review and case report.
J Craniomandib Pract.
1989;
7
58-62
-
155 Owens D G C. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge; 1st ed. Cambridge University Press 1999
-
156
Owens D G C, Johnstone E C, Frith C M.
Spontaneous involuntary disorders of movement.
Arch Gen Psychiatry.
1982;
39
452-461
-
157
Ozelius L, Kramer P L, Moskowitz C B, Kwiatkowski D J, Brin M F, Bressman S B, Schuback D E, Falk C T, Risch N, de Leon D, Burke R E, Haines J, Gusella J F, Fahn S, Breakefield X O.
Human gene for torsion dystonia located on chromosome 9q32-34.
Neuron.
1989;
2
1427-1434
-
158
Paulsen J S, Caligiuri M P, Palmer B, McAdams L A, Jeste D V.
Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.
Psychopharmacology (Berlin).
1996;
123
307-314
-
159
Polizos P, Engelhardt D M, Hoffman S P.
Neurological consequences of psychotropic drug withdrawal in schizophrenic children.
J Autism Child Schizo.
1973;
3
247-253
-
160
Postolache T T, Londono J H, Halem R G, Newmark M D.
Electroconvulsive therapy in tardive dystonia.
Convuls Ther.
1995;
11
275-279
-
161
Povlsen U J, Noring U, Fog R.
Tolerability and therapeutic effect of clozapine.
Acta Psychiatr Scand.
1985;
71
176-185
-
162
Quitkin F, Rifkin R, Gouchfeld L, Klein D F.
Tardive dyskinesia: Are first signs reversible?.
Am J Psychiatry.
1977;
134
84-87
-
163
Raja M.
Tardive dystonia: prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients.
Eur Arch Psychiatry Clin Neurosci.
1995;
245
145-151
-
164
Richardson M A, Haugland M A, Pass R, Craig T J.
The prevalence of tardive dyskinesia in a mentally retarded population.
Psychopharmacol Bull.
1986;
22
243-249
-
165
Richardson M A, Suckow R, Whittaker R, Boggiano W, Sziraki I, Kushner H, Perumal A.
The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia.
Psychopharmacol Bull.
1989;
25
47-51
-
166
Ritchie E C, Bridenbaugh R H, Jabbari B.
Acute generalized myoclonus following buspirone administration.
J Clin Psychiatry.
1988;
49
242-243
-
167
Sachdev P.
The prevalence of tardive dystonia in patients with chronic schizophrenia.
Aust N Z J Psychiatry.
1991;
25
446-448
-
168
Sachdev P.
Clinical characteristics of 15 patients with tardive dystonia.
Am J Psychiatry.
1993;
150
498-500
-
169 Sachdev P. Akathisia and restless legs. Cambridge; 1st ed. Cambridge University Press 1995
-
170
Sachdev P, Loneragan C.
Intravenous challenges of benztropine and propranolol in tardive akathisia.
Psychopharmacology.
1993;
116
324-331
-
171
Sachdev P, Hume F, Toohey P, Doutney C.
Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.
Acta Psychiatr Scand.
1996;
93
451-459
-
172
Safferman A Z, Lieberman J A, Pollack S, Kane J M.
Akathisia and clozapine treatment (letter).
J Clin Psychopharmacol.
1993;
13
286-287
-
173
Sahoo R N, Mitra G C, Mohanty P C.
Irreversible drug induced parkinsonism.
J Assoc Physicians India.
1975;
23
529-530
-
174
Sajatovic M, Meltzer H Y.
Clozapine-induced myoclonus and generalized seizures.
Biol Psychiatry.
1996;
39
367-370
-
175
Saltz B, Woerner M G, Kane J M, Lieberman J A, Alvir J M J, Bergmann K J, Blank K, Koblenzer J, Kahaner K.
Prospective study of tardive dyskinesia in the elderly.
JAMA.
1991;
266
2402-2406
-
176
Sandyk R, Derpapas H.
Successful treatment of respiratory dyskinesia with picoTesla range magnetic fields.
Int J Neurosci.
1994;
75
91-102
-
177
Sandyk R, Fisher H.
Serotonin in involuntary movement disorders.
Int J Neurosci.
1988;
42
185-205
-
178
Schmid W R, Jarcho L W.
Persistent dyskinesias following phenothiazine treatment.
Arch Neurol.
1966;
14
369-377
-
179
Schönecker M.
Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.
Nervenarzt.
1957;
28
35
-
180
Schooler N R, Kane J M.
Research diagnoses for tardive dyskinesia.
Arch Gen Psychiatry.
1982;
39
486-487
-
181
Schrodt G R, Wright J H, Simpson R, Moore D P, Chase S.
Treatment of tardive dyskinesia with propranolol.
J Clin Psychiatry.
1982;
43
328-331
-
182
Schultz S K, Arndt S, Ho B-C, Oliver S E, Andreasen N C.
Impaired glucose tolerance and abnormal movements in patients with schizophrenia.
Am J Psychiatry.
1999;
156
640-642
-
183
Seeman M V, Patel J, Pyke J.
Tardive dyskinesia with Tourette-like syndrome.
J Clin Psychiatry.
1981;
42
357-358
-
184
Sethi K D, Hess D C, Harp R J.
Prevalence of dystonia in veterans on chronic antipsychotic therapy.
Mov Disord.
1990;
5
319-321
-
185
Sigwald J, Bouttier D, Raymond C, Piot C.
Quatre cas de dyskinésie facio-bucco-linguo-masticatice a évolution prolongée secondaire à un traitement par les neuroleptiques.
Rev Neurol (Paris).
1959;
100
751-755
-
186
Simpson G, Amuso D, Blair J H, Farkas T.
Phenothiazine-produced extra-pyramidal system disturbance.
Arch Gen Psychiatry.
1964;
10
199-208
-
187
Simpson G, Lee J M, Shivastava R K.
Clozapine in tardive dyskinesia.
Psychopharmacology.
1978;
56
75-80
-
188
Singh M M, Becker R, Pitman R K, Nasrallah H A, Lal H, Dufresne R L, Weber S S, McCalley-Whitters M.
Diazepam-induced changes in tardive dyskinesia: suggestion for a new conceptual model.
Biol Psychiatry.
1982;
17
729-742
-
189
Small J G, Milstein V, Marhenke J D, Hall D D, Kellams J J.
Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis.
J Clin Psychiatry.
1987;
48
263-267
-
190
Smith J M, Strizich M, Klass D.
Drug history and tardive dyskinesia.
Am J Psychiatry.
1978;
135
1402-1403
-
191
Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A.
Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
J Clin Psychiatry.
1997;
58
318-322
-
192
Stacy M, Jankovic J.
Tardive tremor.
Mov Disord.
1992;
7
53-57
-
193
Stahl S M.
Tardive Tourette syndrome in an autistic patient after long term neuroleptic administration.
Am J Psychiatry.
1980;
137
1267-1269
-
194
Storey E, Lloyd J.
Tardive tremor.
Mov Disord.
1997;
12
808-810
-
195
Sweet R A, Mulsant B H, Gupta B, Rifai A H, Pasternak R E, McEachran A, Zubenko G S.
Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.
Arch Gen Psychiatry.
1995;
52
478-486
-
196
Szymanski S, Lieberman J A, Safferman A, Galkowski B.
Rib fractures as an unusual complication of severe tardive dystonia (letter).
J Clin Psychiatry.
1993;
54
160
-
197
Tamminga C A, Thaker G K, Moran M, Kakigi T, Gao X M.
Clozapine in tardive dyskinesia: observations from human and animal model studies.
J Clin Psychiatry.
1994;
55 (9 suppl B)
102-106
-
198 Tardive Dyskinesia .A Task Force Report of the American Psychiatric Association. Washington (DC); American Psychiatric Association 1992
-
199
Tarsy D, Kaufman D, Sethi K D, Rivner M H, Molho E, Factor S.
An open-label study of botulinum toxin A for treatment of tardive dystonia.
Clin Neuropharmacol.
1997;
20
90-93
-
200
Thaker G K, Nguyen J A, Strauss M E, Jacobson R, Kaup B A, Tamminga C A.
Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
Am J Psychiatry.
1990;
147
445-451
-
201
Toenniessen L M, Casey D E, McFarland B H.
Tardive dyskinesia in the aged. Duration of treatment relationship.
Arch Gen Psychiatry.
1985;
42
278-284
-
202
Tollefson G D, Beasley C M Jr, Tamura R N, Tran P V, Potvin J H.
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Am J Psychiatry.
1997;
154
1248-1254
-
203
Tominaga H, Fukuzako H, Izumi K, Koja T, Fukuda T, Fujii H, Matsumoto K, Sonoda H, Imamura K.
Tardive myoclonus (letter).
Lancet.
1987;
8528
322
-
204
van Harten P N, Matroos G E, Hoek H W, Kahn R S.
The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao Extrapyramidal Syndromes Study I.
Schizophr Res.
1996;
19
195-203
-
205
van Harten P N, Hoek H W, Matroos G E, Koeter M, Kahn R S.
The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II.
Schizophr Res.
1997;
26
235-242
-
206
van Harten P N, Hoek H W, Matroos G E, Koeter M, Kahn R S.
Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III.
Am J Psychiatry.
1998;
155
565-567
-
207
van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R.
Tardive dyskinesia: who is at risk?.
Acta Psychiatr Scand.
1997;
96
206-216
-
208
Waddington J L, Youssef H A, Dolphin C, Kinsella A.
Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.
Arch Gen Psychiatry.
1987;
44
907-912
-
209
Waddington J L, O'Callaghan E, Larkin C.
Schizophrenia, long-term neuroleptic treatment and mechanism of late-onset side effects.
Psychopharmacology.
1988;
96 (suppl)
29
-
210
Waddington J L, Youssef H A, Kinsella A.
Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia.
Psychol Med.
1990;
20
835-842
-
211
Weetman J, Anderson I M, Gregory R P, Gill S S.
Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia (letter).
J Neurol Neurosurg Psychiatry.
1997;
63
554-556
-
212
Wegner J C, Catalano F, Gibralter J, Kane J M.
Schizophrenics with tardive dyskinesia - neuropsychological deficit and family psychopathology.
Arch Gen Psychiatry.
1985;
42
860-865
-
213
Weiner W J, Luby E D.
Tardive akathisia.
J Clin Psychiatry.
1983;
44
417-419
-
214
Wilson J A, Smith R G.
Relation between elderly and AIDS patients with drug-induced Parkinson's disease.
Lancet.
1987;
2
686
-
215
Winsberg B G, Hurwic M J, Perel J.
Neurochemistry of withdrawal emergent symptoms in children.
Psychopharmacol Bull.
1977;
13
38-40
-
216
Wojcik J D, Falk W E, Fink J S, Cole J O, Gelenberg A J.
A review of 32 cases of tardive dystonia.
Am J Psychiatry.
1991;
148
1055-1059
-
217
Yadalam K G, Korn M L, Simpson G M.
Tardive dystonia: four case histories.
J Clin Psychiatry.
1990;
51
17-20
-
218
Yagi G, Itoh H.
Follow-up study of 11 patients with potentially reversible tardive dyskinesia.
Am J Psychiatry.
1987;
144
1496-1498
-
219
Yassa R.
Functional impairment in tardive dyskinesia: medical and psychosocial dimensions.
Acta Psychiatr Scand.
1989;
80
64-67
-
220 Yassa R. Other factors in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 99-103
-
221
Yassa R, Ananth J.
Familial tardive dyskinesia.
Am J Psychiatry.
1981;
138
1618-1619
-
222 Yassa R, Jeste D V. Gender as a factor in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 26-40
-
223
Yassa R, Jones B D.
The complications of tardive dyskinesia.
Psychosomatics.
1985;
26
305-318
-
224
Yassa R, Nair N P V.
Incidence of tardive dyskinesia in an outpatients population.
Psychosomatics.
1984;
25
479-481
-
225 Yassa R, Nair N P V. Anticholinergic drugs as factors in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 117-125
-
226
Yassa R, Nair N P V, Dimitry R.
Prevalence of tardive dystonia.
Acta Psychiatr Scand.
1986a;
73
629-633
-
227
Yassa R, Nair N P V, Schwartz G.
Early versus late onset psychosis and tardive dyskinesia.
Biol Psychiatry.
1986b;
21
1291-1297
-
228
Yassa R, Nair N P V, Iskandar H.
A comparison of severe tardive dystonia and severe tardive dyskinesia.
Acta Psychiatr Scand.
1989;
80
155-159
-
229
Yassa R, Nair N P V, Iskandar H, Schwartz G.
Factors in the development of severe forms of tardive dyskinesia.
Am J Psychiatry.
1990;
147
1156-1163
-
230 Yassa R, Nair N P V, Jeste D V. Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997
-
231
Yazici O, Kantemir E, Tastaban Y, Ocok A, Ozguroglu M.
Spontaneous improvement of tardive dystonia during mania.
Br J Psychiatry.
1991;
158
847-850
-
232
Youssef H A, Waddington J L.
Mortality and morbidity in tardive dyskinesia: association in chronic schizophrenia.
Acta Psychiatr Scand.
1987;
75
74-77
M. Maršálek
Mental Hospital Prague Bohnice
Ústavní 91
181 02 Prague 8
Czech Republic
Phone: 00420-2-84016242
Fax: 00420-2-8558097
Email: marsalek@plbohnice.cz
